Sleep apnea prevalence in chronic heart failure patients with severe left ventricle systolic dysfunction

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F17%3A00067627" target="_blank" >RIV/00159816:_____/17:00067627 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Sleep apnea prevalence in chronic heart failure patients with severe left ventricle systolic dysfunction

Popis výsledku v původním jazyce

Background. While sleep apnea (SA) might be a modifiable cardiovascular risk factor, recent data suggest that SA is severely underdiagnosed in chronic heart failure (CHF) patients especially with severe left ventricle systolic dysfunction. We therefore investigated the prevalence of SA in these patients. Methods. We prospectively studied 192 CHF patients with severe left ventricle dysfunction. All subjects were in stable condition and underwent sleep evaluations using Embletta Gold during hospitalization. Using the apnea-hypopnea index (AHI), groups were defined as patients without SA (&lt;5 events/h), mild SA (5-15 events/h), moderate SA (15-30 events/h), and severe SA (GREATER-THAN OR EQUAL TO30 events/h). Results. Using a threshold of AHIGREATER-THAN OR EQUAL TO5 events/h, SA was present in 75% of patients with CHF and severe systolic dysfunction. Moderate to severe SA was present in 48.4% of them. Conclusion. There is a high prevalence of SA in patients with CHF with severe systolic dysfunction. Whether diagnosis and treatment of SA will significantly improve outcomes in these patients remains to be determined.

Název v anglickém jazyce

Sleep apnea prevalence in chronic heart failure patients with severe left ventricle systolic dysfunction

Popis výsledku anglicky

Background. While sleep apnea (SA) might be a modifiable cardiovascular risk factor, recent data suggest that SA is severely underdiagnosed in chronic heart failure (CHF) patients especially with severe left ventricle systolic dysfunction. We therefore investigated the prevalence of SA in these patients. Methods. We prospectively studied 192 CHF patients with severe left ventricle dysfunction. All subjects were in stable condition and underwent sleep evaluations using Embletta Gold during hospitalization. Using the apnea-hypopnea index (AHI), groups were defined as patients without SA (&lt;5 events/h), mild SA (5-15 events/h), moderate SA (15-30 events/h), and severe SA (GREATER-THAN OR EQUAL TO30 events/h). Results. Using a threshold of AHIGREATER-THAN OR EQUAL TO5 events/h, SA was present in 75% of patients with CHF and severe systolic dysfunction. Moderate to severe SA was present in 48.4% of them. Conclusion. There is a high prevalence of SA in patients with CHF with severe systolic dysfunction. Whether diagnosis and treatment of SA will significantly improve outcomes in these patients remains to be determined.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

20602 - Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BIOMEDICAL PAPERS-OLOMOUC

ISSN

1213-8118

e-ISSN

—

Svazek periodika

161

Číslo periodika v rámci svazku

S1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

3

Strana od-do

"S12"-"S14"

Kód UT WoS článku

000428945000002

EID výsledku v databázi Scopus

—